1. Medtech Insight
  2. >>Business
  3. >>R&D

Results Recap: PRODIGY Supports Medtronic’s Opioid-Related Risk Predictor; Axionics' SNM System For Incontinence Succeeds

 
• By Reed Miller

Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 11 through Feb. 21, includes published results from trials of Medtronic's respiratory compromise monitoring system, Agile's contraceptive patch, Affluent's EVAR device for AAA, Abbott's flash glucose monitor, and Axionic's anti-incontinence device.

Results Recap, Clinical Trials
• Source: shutterstock.com

[Editors Note:Results Recap is Medtech Insights regular review of important medical device trial presentations as tracked by Informa’s MedDeviceTracker. Click here to request a demonstration. For an archive of previous Results Recaps and Starts & Stops, our regular updates on trial announcements, visit the Tracking Trials page.]

Top-line results from a comparative wear study of the adhesion of Agile Therapeutics Twirla contraceptive patch show Twirla is non-inferior to Xulane, the generic version of Janseen’s Ortho Evra

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

More from Business

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.